Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBITDA (2021 - 2025)

Historic EBITDA for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.8 million.

  • InMed Pharmaceuticals' EBITDA fell 576.79% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 1088.06%. This contributed to the annual value of -$7.9 million for FY2025, which is 309.68% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' EBITDA stood at -$1.8 million, which was down 576.79% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' EBITDA ranged from a high of -$472234.0 in Q2 2023 and a low of -$7.9 million during Q2 2022
  • Its 5-year average for EBITDA is -$2.6 million, with a median of -$2.1 million in 2022.
  • In the last 5 years, InMed Pharmaceuticals' EBITDA soared by 9399.96% in 2023 and then tumbled by 32961.14% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' EBITDA (Quarter) stood at -$4.3 million in 2021, then surged by 50.94% to -$2.1 million in 2022, then increased by 22.39% to -$1.6 million in 2023, then crashed by 37.47% to -$2.2 million in 2024, then rose by 18.79% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, -$1.8 million for Q2 2025, and -$2.1 million during Q1 2025.